HIFU improves the therapeutic efficacy of dendritic cell vaccine in mouse melanoma model
Bumseo Baek1,2, Hyunmi Park1,2, Ji-Woong Choi1,Eun-Young Lee1, Sujin Yoon1, Sang-Uk Seo1,2, Je-In Youn1,2, Seung-Yong Seong1,2,3*
1Wide River Institute of Immunology, Seoul National University College of Medicine, Hongcheon, Republic of Korea
2Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
3Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea
The tumor treatment via HIFU (High Intensity Focused Ultrasound) can evaluate the immune system and potentially enhance the body's ability to manage cancer. Once the tumor cell is destroyed by HIFU treatment, DAMP (Damage Associated Molecular Factor) and cellular debris are released to provide tumor-specific antigens and enhance anti-tumor immune response locally and systemically. In addition, thermal ablation induces local inflammation, stimulates the recruitment of immune effector cells, and activates anti-tumor immunity, all of which can increase the body’s resistance to cancer. Tumor debris can activate dendritic cells and other anti-tumor adaptive immunity cells, such as CD8+ T cells. The synergistic effect of HIFU therapy was evaluated when combined with DC vaccine delivering tumor antigen in mouse melanoma model. Our results suggest that combinatorial treatment of DC vaccine and HIFU could be promising therapy in melanoma model.